IL256424B2 - Methods of treating autoimmune and alloimmune disorders - Google Patents

Methods of treating autoimmune and alloimmune disorders

Info

Publication number
IL256424B2
IL256424B2 IL256424A IL25642417A IL256424B2 IL 256424 B2 IL256424 B2 IL 256424B2 IL 256424 A IL256424 A IL 256424A IL 25642417 A IL25642417 A IL 25642417A IL 256424 B2 IL256424 B2 IL 256424B2
Authority
IL
Israel
Prior art keywords
antibody
seq
cdr
composition
amino acid
Prior art date
Application number
IL256424A
Other languages
English (en)
Hebrew (he)
Other versions
IL256424B1 (en
IL256424A (en
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of IL256424A publication Critical patent/IL256424A/en
Publication of IL256424B1 publication Critical patent/IL256424B1/en
Publication of IL256424B2 publication Critical patent/IL256424B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL256424A 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders IL256424B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Publications (3)

Publication Number Publication Date
IL256424A IL256424A (en) 2018-02-28
IL256424B1 IL256424B1 (en) 2024-05-01
IL256424B2 true IL256424B2 (en) 2024-09-01

Family

ID=57585852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256424A IL256424B2 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Country Status (12)

Country Link
US (3) US20180169240A1 (enExample)
EP (1) EP3313417A4 (enExample)
JP (1) JP6963509B2 (enExample)
KR (1) KR20180020296A (enExample)
CN (1) CN108348600A (enExample)
AU (2) AU2016282782A1 (enExample)
CA (1) CA2990662A1 (enExample)
EA (1) EA038567B1 (enExample)
HK (1) HK1254030A1 (enExample)
IL (1) IL256424B2 (enExample)
MX (2) MX2017016835A (enExample)
WO (1) WO2016210172A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
EP4273165A3 (en) 2016-04-29 2023-12-20 Pfizer Inc. Interferon beta antibodies and uses thereof
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
WO2019098212A1 (en) 2017-11-14 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
JP2022532282A (ja) 2019-05-15 2022-07-14 中外製薬株式会社 抗原結合分子、薬学的組成物、および方法
BR112022006014A2 (pt) * 2019-10-16 2022-07-12 Chugai Pharmaceutical Co Ltd Anticorpo, composição farmacêutica e método
CA3187866A1 (en) * 2020-08-06 2022-02-10 Jaime Morales ARIAS Inflammatory cytokines and fatigue in subject with a complement mediated disease
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079174A1 (en) * 1999-08-23 2005-04-14 Biocrystal, Ltd. Methods and compositions for immunotherapy of B cell involvement in promotion of a disease condition comprising multiple sclerosis
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538384A (en) * 2002-09-06 2009-04-30 Alexion Pharma Inc Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2009132058A2 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
CN102597005A (zh) * 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
PT2914291T (pt) * 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079174A1 (en) * 1999-08-23 2005-04-14 Biocrystal, Ltd. Methods and compositions for immunotherapy of B cell involvement in promotion of a disease condition comprising multiple sclerosis
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof

Also Published As

Publication number Publication date
CN108348600A (zh) 2018-07-31
KR20180020296A (ko) 2018-02-27
MX2017016835A (es) 2018-08-01
US20220249664A1 (en) 2022-08-11
EA201890106A1 (ru) 2018-05-31
BR112017027578A2 (pt) 2018-08-28
AU2022215307A1 (en) 2022-09-08
HK1254030A1 (zh) 2019-07-12
WO2016210172A1 (en) 2016-12-29
US20250295768A1 (en) 2025-09-25
AU2022215307B2 (en) 2025-09-04
IL256424B1 (en) 2024-05-01
AU2016282782A1 (en) 2018-01-18
EP3313417A4 (en) 2019-06-12
IL256424A (en) 2018-02-28
MX2023002021A (es) 2023-03-15
JP6963509B2 (ja) 2021-11-10
EA038567B1 (ru) 2021-09-15
NZ738570A (en) 2025-05-02
EP3313417A1 (en) 2018-05-02
JP2018526330A (ja) 2018-09-13
CA2990662A1 (en) 2016-12-29
US20180169240A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US20250295768A1 (en) Methods of treating autoimmune and alloimmune disorders
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
CN108779171B (zh) 抗补体因子c1q的fab片段及其应用
AU2018236267B2 (en) Methods for treating complement-mediated diseases and disorders
US9475872B2 (en) Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
TWI669314B (zh) 針對ｔａｕ之抗體及其用途
JP2025081304A (ja) Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法
US10875916B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F
JP2019507107A (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体及びその使用
CN109311992B (zh) 用于治疗t细胞介导疾病的新型抗cd6抗体
US20210301002A1 (en) Anti-hspa5 antibodies and uses thereof
EP3487531A1 (en) Compositions and methods for treating frontotemporal dementia
TW202302650A (zh) 針對dll3的結合分子及其應用
US20180207271A1 (en) Il-26 inhibitors
JP2019508415A (ja) 抗シトルリン化ｈｌａポリペプチド抗体及びその使用
US20250145696A1 (en) Methods for treating complement-mediated diseases and disorders
BR112017027578B1 (pt) Método in vitro de monitoramento da eficácia de um método de tratamento que compreende administrar um anticorpo anti-c1s
BR122024005916A2 (pt) Uso de um anticorpo que se liga especificamente ao componente 1s (c1s) do complemento no tratamento de distúrbios autoimunes
HK1262078A1 (en) Anti-complement factor c1q fab fragments and uses thereof
HK1262078B (en) Anti-complement factor c1q fab fragments and uses thereof